[	[	(	O	O	
Experimental	Experimental	JJ	B-NP	O	
and	and	CC	I-NP	O	
clinical	clinical	JJ	I-NP	O	
studies	study	NNS	I-NP	O	
of	of	IN	B-PP	O	
flomoxef	flomoxef	NN	B-NP	O	
in	in	IN	B-PP	O	
the	the	DT	B-NP	O	
field	field	NN	I-NP	O	
of	of	IN	B-PP	O	
obstetrics	obstetric	NNS	B-NP	O	
and	and	CC	I-NP	O	
gynecology	gynecology	NN	I-NP	O	
.	.	.	O	O	

Representative	Representative	JJ	B-NP	O	
Committee	Committee	NNP	I-NP	O	
Members	Members	NNP	I-NP	O	
of	of	IN	B-PP	O	
the	the	DT	B-NP	O	
Research	Research	NNP	I-NP	O	
Team	Team	NNP	I-NP	O	
for	for	IN	B-PP	O	
Infections	Infection	NNPS	B-NP	O	
in	in	IN	B-PP	O	
the	the	DT	B-NP	O	
Field	Field	NNP	I-NP	O	
of	of	IN	B-PP	O	
Obstetrics	Obstetrics	NNP	B-NP	O	
and	and	CC	I-NP	O	
Gynecology	Gynecology	NNP	I-NP	O	
]	]	)	O	O	
.	.	.	O	O	

Flomoxef	Flomoxef	NN	B-NP	O	
(	(	(	O	O	
FMOX	FMOX	NN	B-NP	B-protein	
)	)	)	O	O	
has	have	VBZ	B-VP	O	
a	a	DT	B-NP	O	
broad	broad	JJ	I-NP	O	
antibacterial	antibacterial	JJ	I-NP	O	
spectrum	spectrum	NN	I-NP	O	
against	against	IN	B-PP	O	
Gram	Gram	NN	B-NP	B-protein	
-	-	HYPH	B-NP	O	
positive	positive	JJ	I-NP	O	
and	and	CC	I-NP	O	
Gram	Gram	NN	I-NP	O	
-	-	HYPH	B-NP	O	
negative	negative	JJ	I-NP	O	
bacteria	bacteria	NNS	I-NP	O	
;	;	:	O	O	
especially	especially	RB	B-ADVP	O	
its	its	PRP$	B-NP	O	
potent	potent	JJ	I-NP	O	
antibacterial	antibacterial	JJ	I-NP	O	
activity	activity	NN	I-NP	O	
against	against	IN	B-PP	O	
Staphylococcus aureus	Staphylococcus_aureus	NNP	B-NP	O	
is	be	VBZ	B-VP	O	
a	a	DT	B-NP	O	
significant	significant	JJ	I-NP	O	
advantage	advantage	NN	I-NP	O	
that	that	WDT	B-NP	O	
may	may	MD	B-VP	O	
not	not	RB	I-VP	O	
be	be	VB	I-VP	O	
found	find	VBN	I-VP	O	
with	with	IN	B-PP	O	
other	other	JJ	B-NP	O	
cephem	cephem	NN	I-NP	O	
compounds	compound	NNS	I-NP	O	
.	.	.	O	O	

In	In	IN	B-PP	O	
our	our	PRP$	B-NP	O	
determination	determination	NN	I-NP	O	
of	of	IN	B-PP	O	
its	its	PRP$	B-NP	O	
antibacterial	antibacterial	JJ	I-NP	O	
potency	potency	NN	I-NP	O	
against	against	IN	B-PP	O	
various	various	JJ	B-NP	O	
clinical	clinical	JJ	I-NP	O	
isolates	isolate	NNS	I-NP	O	
obtained	obtain	VBN	B-VP	O	
from	from	IN	B-PP	O	
clinical	clinical	JJ	B-NP	O	
materials	material	NNS	I-NP	O	
(	(	(	O	O	
amniotic	amniotic	JJ	B-NP	O	
fluid	fluid	NN	I-NP	O	
,	,	,	O	O	
intrauterine	intrauterine	JJ	B-NP	O	
secretions	secretion	NNS	I-NP	O	
,	,	,	O	O	
exudates	exudate	NNS	B-NP	O	
of	of	IN	B-PP	O	
the	the	DT	B-NP	O	
pelvic	pelvic	JJ	I-NP	O	
dead	dead	JJ	I-NP	O	
space	space	NN	I-NP	O	
)	)	)	O	O	
of	of	IN	B-PP	O	
patients	patient	NNS	B-NP	O	
with	with	IN	B-PP	O	
various	various	JJ	B-NP	O	
infections	infection	NNS	I-NP	O	
,	,	,	O	O	
we	we	PRP	B-NP	O	
obtained	obtain	VBD	B-VP	O	
results	result	NNS	B-NP	O	
representing	represent	VBG	B-VP	O	
specific	specific	JJ	B-NP	O	
features	feature	NNS	I-NP	O	
of	of	IN	B-PP	O	
this	this	DT	B-NP	O	
drug	drug	NN	I-NP	O	
.	.	.	O	O	

From	From	IN	B-PP	O	
the	the	DT	B-NP	O	
results	result	NNS	I-NP	O	
,	,	,	O	O	
the	the	DT	B-NP	O	
drug	drug	NN	I-NP	O	
may	may	MD	B-VP	O	
be	be	VB	I-VP	O	
expected	expect	VBN	I-VP	O	
to	to	TO	I-VP	O	
produce	produce	VB	I-VP	O	
an	an	DT	B-NP	O	
excellent	excellent	JJ	I-NP	O	
effect	effect	NN	I-NP	O	
in	in	IN	B-PP	O	
the	the	DT	B-NP	O	
treatment	treatment	NN	I-NP	O	
of	of	IN	B-PP	O	
various	various	JJ	B-NP	O	
infections	infection	NNS	I-NP	O	
.	.	.	O	O	

Our	Our	PRP$	B-NP	O	
study	study	NN	I-NP	O	
on	on	IN	B-PP	O	
drug	drug	NN	B-NP	O	
concentrations	concentration	NNS	I-NP	O	
in	in	IN	B-PP	O	
body	body	NN	B-NP	O	
fluids	fluid	NNS	I-NP	O	
and	and	CC	O	O	
genital	genital	JJ	B-NP	O	
tissues	tissue	NNS	I-NP	O	
demonstrated	demonstrate	VBD	B-VP	O	
a	a	DT	B-NP	O	
good	good	JJ	I-NP	O	
transfer	transfer	NN	I-NP	O	
of	of	IN	B-PP	O	
this	this	DT	B-NP	O	
drug	drug	NN	I-NP	O	
into	into	IN	B-PP	O	
various	various	JJ	B-NP	O	
tissues	tissue	NNS	I-NP	O	
;	;	:	O	O	
in	in	IN	B-PP	O	
every	every	DT	B-NP	O	
tissue	tissue	NN	I-NP	O	
examined	examine	VBN	B-VP	O	
,	,	,	O	O	
the	the	DT	B-NP	O	
drug	drug	NN	I-NP	O	
administered	administer	VBN	B-VP	O	
by	by	IN	B-PP	O	
the	the	DT	B-NP	O	
usual	usual	JJ	I-NP	O	
method	method	NN	I-NP	O	
in	in	IN	B-PP	O	
the	the	DT	B-NP	O	
usual	usual	JJ	I-NP	O	
dose	dose	NN	I-NP	O	
yielded	yield	VBD	B-VP	O	
a	a	DT	B-NP	O	
concentration	concentration	NN	I-NP	O	
exceeding	exceed	VBG	B-VP	O	
MIC	MIC	NN	B-NP	O	
for	for	IN	B-PP	O	
principal	principal	JJ	B-NP	O	
pathogens	pathogen	NNS	I-NP	O	
,	,	,	O	O	
thus	thus	RB	B-ADVP	O	
promising	promise	VBG	B-VP	O	
a	a	DT	B-NP	O	
good	good	JJ	I-NP	O	
clinical	clinical	JJ	I-NP	O	
response	response	NN	I-NP	O	
.	.	.	O	O	

Indeed	Indeed	RB	B-ADVP	O	
a	a	DT	B-NP	O	
high	high	JJ	I-NP	O	
clinical	clinical	JJ	I-NP	O	
efficacy	efficacy	NN	I-NP	O	
rate	rate	NN	I-NP	O	
of	of	IN	B-PP	O	
90.1	90.1	CD	B-NP	O	
%	%	NN	I-NP	O	
(	(	(	O	O	
good	good	JJ	B-ADJP	O	
to	to	TO	B-PP	O	
very	very	RB	B-NP	O	
good	good	JJ	I-NP	O	
responses	response	NNS	I-NP	O	
)	)	)	O	O	
was	be	VBD	B-VP	O	
obtained	obtain	VBN	I-VP	O	
in	in	IN	B-PP	O	
a	a	DT	B-NP	O	
clinical	clinical	JJ	I-NP	O	
trial	trial	NN	I-NP	O	
involving	involve	VBG	B-VP	O	
222	222	CD	B-NP	O	
cases	case	NNS	I-NP	O	
.	.	.	O	O	

Administration	Administration	NN	B-NP	O	
of	of	IN	B-PP	O	
the	the	DT	B-NP	O	
drug	drug	NN	I-NP	O	
in	in	IN	B-PP	O	
2	2	CD	B-NP	O	
g	g	NN	I-NP	O	
quantity	quantity	NN	I-NP	O	
daily	daily	RB	B-ADVP	O	
produced	produce	VBD	B-VP	O	
a	a	DT	B-NP	O	
high	high	JJ	I-NP	O	
response	response	NN	I-NP	O	
rate	rate	NN	I-NP	O	
of	of	IN	B-PP	O	
92.8	92.8	CD	B-NP	O	
%	%	NN	I-NP	O	
.	.	.	O	O	

It	It	PRP	B-NP	O	
was	be	VBD	B-VP	O	
especially	especially	RB	B-ADJP	O	
noteworthy	noteworthy	JJ	I-ADJP	O	
that	that	IN	B-SBAR	O	
a	a	DT	B-NP	O	
good	good	JJ	I-NP	O	
response	response	NN	I-NP	O	
was	be	VBD	B-VP	O	
obtained	obtain	VBN	I-VP	O	
in	in	IN	B-PP	O	
30	30	CD	B-NP	O	
of	of	IN	B-PP	O	
32	32	CD	B-NP	O	
cases	case	NNS	I-NP	O	
(	(	(	O	O	
93.8	93.8	CD	B-NP	O	
%	%	NN	I-NP	O	
)	)	)	O	O	
in	in	IN	B-PP	O	
which	which	WDT	B-NP	O	
other	other	JJ	B-NP	O	
cephem	cephem	NN	I-NP	O	
compounds	compound	NNS	I-NP	O	
had	have	VBD	B-VP	O	
failed	fail	VBN	I-VP	O	
.	.	.	O	O	

In	In	IN	B-PP	O	
evaluation	evaluation	NN	B-NP	O	
of	of	IN	B-PP	O	
the	the	DT	B-NP	O	
bacteriological	bacteriological	JJ	I-NP	O	
effect	effect	NN	I-NP	O	
,	,	,	O	O	
furthermore	furthermore	RB	B-ADVP	O	
,	,	,	O	O	
the	the	DT	B-NP	O	
drug	drug	NN	I-NP	O	
showed	show	VBD	B-VP	O	
an	an	DT	B-NP	O	
excellent	excellent	JJ	I-NP	O	
rate	rate	NN	I-NP	O	
of	of	IN	B-PP	O	
bacterial	bacterial	JJ	B-NP	O	
elimination	elimination	NN	I-NP	O	
.	.	.	O	O	

In	In	IN	B-PP	O	
conclusion	conclusion	NN	B-NP	O	
,	,	,	O	O	
this	this	DT	B-NP	O	
drug	drug	NN	I-NP	O	
is	be	VBZ	B-VP	O	
expected	expect	VBN	I-VP	O	
to	to	TO	I-VP	O	
be	be	VB	I-VP	O	
greatly	greatly	RB	B-ADJP	O	
useful	useful	JJ	I-ADJP	O	
in	in	IN	B-PP	O	
the	the	DT	B-NP	O	
light	light	NN	I-NP	O	
of	of	IN	B-PP	O	
its	its	PRP$	B-NP	O	
good	good	JJ	I-NP	O	
transfer	transfer	NN	I-NP	O	
into	into	IN	B-PP	O	
genital	genital	JJ	B-NP	O	
tissues	tissue	NNS	I-NP	O	
and	and	CC	O	O	
its	its	PRP$	B-NP	O	
strong	strong	JJ	I-NP	O	
antibacterial	antibacterial	JJ	I-NP	O	
activities	activity	NNS	I-NP	O	
against	against	IN	B-PP	O	
Gram	Gram	NN	B-NP	B-protein	
-	-	HYPH	B-NP	O	
positive	positive	JJ	I-NP	O	
cocci	coccus	NNS	I-NP	O	
,	,	,	O	O	
Gram	Gram	NN	B-NP	B-protein	
-	-	HYPH	I-NP	O	
negative	negative	JJ	I-NP	O	
bacteria	bacteria	NNS	I-NP	O	
and	and	CC	I-NP	O	
anaerobes	anaerobe	NNS	I-NP	O	
as	as	RB	B-CONJP	O	
well	well	RB	I-CONJP	O	
as	as	IN	I-CONJP	O	
against	against	IN	B-PP	O	
multiple	multiple	JJ	B-NP	O	
bacterial	bacterial	JJ	I-NP	O	
infections	infection	NNS	I-NP	O	
predominating	predominate	VBG	B-VP	O	
among	among	IN	B-PP	O	
women	woman	NNS	B-NP	O	
with	with	IN	B-PP	O	
genital	genital	JJ	B-NP	O	
infections	infection	NNS	I-NP	O	
.	.	.	O	O	

